The 3P Laboratory (Pharmacokinetics (PK), Pharmacodynamics (PD) and Pharmacogenetics (PG)) was established by the UWCCC more than 25 years ago to support the translational and clinical research activities of our members. The mission of the 3P Laboratory is to advance cancer research by providing expertise;leadership;and bioanalytical assay development, validation and performance in support of the clinical, translational and laboratory research endeavors of UWCCC investigators. The 3P Lab provides UWCCC members with sample acquisition, processing, storage and shipping services for all PK/PD/PG clinical studies. It provides analysis of samples for PK/PD/PG studies in support of multiple NCI grants as well as research conducted by individual UWCCC investigators. In addition, the 3P Lab provides services for investigators in the preclinical setting to support new drug development. Services include generation of tumor xenografts for testing of investigational compounds, as well as evaluating plasma and intra-tumor drug levels in animal models. This service includes development and performance of original assays for new agents;assays to monitor endogenous biochemicals;and genotyping and mutation assays. Finally, the 3P Lab offers access to their bioanalytical instrumentation to trained UWCCC investigators.
The 3P Laboratory (Pharmacokinetics, Pharmacodynamics and Pharmacogenetics) provides analytical support for biospecimens obtained in the clinical trials conducted at the University of Wisconsin Carbone Cancer Center.
|Oberley, Christopher C; Bilger, Andrea; Drinkwater, Norman R (2015) Genetic background determines if Stat5b suppresses or enhances murine hepatocarcinogenesis. Mol Carcinog 54:959-70|
|Wisinski, Kari B; Ledesma, Wendy M; Kolesar, Jill et al. (2015) A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1?,24(S)Dihydroxyvitamin D2) in patients with advanced cancer. J Oncol Pharm Pract 21:416-24|
|Kolesar, Jill M; Pomplun, Marcia; Havighurst, Tom et al. (2015) Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer. J Oncol Pharm Pract 21:128-31|
|Simoncic, Urban; Perlman, Scott; Liu, Glenn et al. (2015) Comparison of NaF and FDG PET/CT for assessment of treatment response in castration-resistant prostate cancers with osseous metastases. Clin Genitourin Cancer 13:e7-e17|
|Zhao, Z; Wang, L; Xu, W (2015) IL-13R?2 mediates PNR-induced migration and metastasis in ER?-negative breast cancer. Oncogene 34:1596-607|
|Chakravarty, Rubel; Hong, Hao; Cai, Weibo (2015) Image-Guided Drug Delivery with Single-Photon Emission Computed Tomography: A Review of Literature. Curr Drug Targets 16:592-609|
|Wu, Jianqiang; Salva, Katrin A; Wood, Gary S (2015) c-CBL E3 ubiquitin ligase is overexpressed in cutaneous T-cell lymphoma: its inhibition promotes activation-induced cell death. J Invest Dermatol 135:861-8|
|LoConte, Noelle K; Razak, Albiruni R A; Ivy, Percy et al. (2015) A multicenter phase 1 study of ? -secretase inhibitor RO4929097 in combination with capecitabine in refractory solid tumors. Invest New Drugs 33:169-76|
|Romens, Sarah E; McDonald, Jennifer; Svaren, John et al. (2015) Associations between early life stress and gene methylation in children. Child Dev 86:303-9|
|Nihal, Minakshi; Wu, Jianqiang; Wood, Gary S (2014) Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy. Arch Biochem Biophys 563:101-7|
Showing the most recent 10 out of 472 publications